Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case–control study

[1]  R. Murray,et al.  Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. , 2015, Schizophrenia bulletin.

[2]  G. Blasi,et al.  Functional Genetic Variation of the Cannabinoid Receptor 1 and Cannabis Use Interact on Prefrontal Connectivity and Related Working Memory Behavior , 2015, Neuropsychopharmacology.

[3]  M. D. Forti,et al.  Different Dopaminergic Abnormalities Underlie Cannabis Dependence and Cannabis-Induced Psychosis , 2014, Biological Psychiatry.

[4]  L. Kegeles,et al.  Striatal Dopamine Release in Schizophrenia Comorbid with Substance Dependence , 2012, Molecular Psychiatry.

[5]  R. Murray,et al.  Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users , 2012, Biological Psychiatry.

[6]  D. Collier,et al.  Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function , 2012, Molecular Psychiatry.

[7]  R. Winkel.  Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-up , 2011 .

[8]  R. van Winkel.  Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. , 2011, Archives of general psychiatry.

[9]  G. Blasi,et al.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia , 2010, Proceedings of the National Academy of Sciences.

[10]  Fabio Sambataro,et al.  Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance , 2010, PloS one.